Related Experiment Video
Updated: Jul 15, 2026
11:35
Screening for Functional Non-coding Genetic Variants Using Electrophoretic Mobility Shift Assay (EMSA) and DNA-affinity Precipitation Assay (DAPA)
Published on: August 21, 2016
Predictive genetic variants for venous thrombosis: what's new?
Irene D Bezemer1, Frits R Rosendaal
1Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
Seminars in Hematology
|April 17, 2007
Summary
Genetic and acquired risk factors contribute to venous thrombosis. This review examines newly identified genetic variants and their unclear associations with thrombosis, providing perspective on candidate predictors.
Area of Science:
- Medical Science
- Genetics
- Epidemiology
Background:
- Venous thrombosis arises from various pathways, influenced by genetic and acquired risk factors.
- Genetic discoveries like factor V Leiden and prothrombin 20210 G-->A have spurred rapid advancements in genetic epidemiology.
- Numerous genetic variants linked to venous thrombosis have emerged, but their associations remain debated.
Purpose of the Study:
- To review candidate genetic predictors of venous thrombosis.
- To critically evaluate the association between newly identified genetic variants and venous thrombosis.
- To provide a balanced perspective on the current evidence for genetic risk factors in venous thrombosis.
Main Methods:
- Literature review of genetic epidemiology studies.
- Analysis of reported associations between genetic variants and venous thrombosis.
- Synthesis of evidence to assess the clinical relevance of candidate predictors.
Main Results:
- Several genetic variants have been investigated as potential risk factors for venous thrombosis.
- Conflicting results and unclear associations have been reported for many newly identified genetic variants.
- The predictive value of many candidate genetic predictors remains uncertain.
Conclusions:
- The identification of genetic risk factors for venous thrombosis is an evolving field.
- Further research is needed to clarify the role of various genetic variants in thrombosis development.
- Distinguishing true predictors from incidental findings is crucial for clinical application.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...